Siddons Law Firm, PLLC investigates GLP-1 medication injury claims for clients who took an FDA-approved, brand-name semaglutide, tirzepatide, dulaglutide, or liraglutide product and were diagnosed with a serious gastrointestinal, ophthalmic, or related complication. The federal multidistrict litigation — In re: Glucagon-Like Peptide-1 Receptor Agonists Products Liability Litigation, MDL No. 3094 — is consolidated in the United States District Court for the Eastern District of Pennsylvania, the same district in which our firm regularly practices. We evaluate claims at no cost, build and pursue qualifying claims, and protect your statute of limitations while we do.
Who Qualifies — Brand-Name Medications Only
Our firm reviews claims involving the eight brand-name medications listed below. We do not accept claims involving compounded semaglutide, compounded tirzepatide, generic GLP-1 products, or any product purchased from a compounding pharmacy, telehealth wellness platform, or med-spa. If you are not sure whether your medication was brand-name or compounded, see our compounded-semaglutide page or call us and we will help you find out.
| Brand Name | Generic Name | Manufacturer | Common Use |
|---|---|---|---|
| Ozempic | Semaglutide | Novo Nordisk | Type 2 diabetes |
| Wegovy | Semaglutide | Novo Nordisk | Chronic weight management |
| Rybelsus | Semaglutide (oral) | Novo Nordisk | Type 2 diabetes |
| Mounjaro | Tirzepatide | Eli Lilly | Type 2 diabetes |
| Zepbound | Tirzepatide | Eli Lilly | Chronic weight management |
| Trulicity | Dulaglutide | Eli Lilly | Type 2 diabetes |
| Saxenda | Liraglutide | Novo Nordisk | Chronic weight management |
| Victoza | Liraglutide | Novo Nordisk | Type 2 diabetes |
COMPOUNDED PRODUCT? If your medication was compounded — sold as “generic semaglutide,” “research-grade,” or through a telehealth weight-loss platform — your situation is different. Read our compounded-semaglutide page for honest information about your options.
How Long You Took the Medication: 30-Day Minimum
To be eligible for our review, you must have taken one of the eight brand-name medications listed above for a minimum of 30 consecutive days. Shorter exposures generally do not meet the threshold required to establish causation.
Qualifying Medical Diagnoses
We review GLP-1 cases in which the client has been diagnosed with one or more of the following injuries that required medical treatment. Suicide is the only injury category for which prior medical treatment is not required.
| Diagnosis | Plain-language description |
|---|---|
| Intraoperative pulmonary aspiration | Aspiration of stomach contents during a surgical procedure under anesthesia. |
| Ileus or bowel obstruction | With or without surgical treatment. |
| Esophageal injury requiring surgery | Surgical intervention required for esophageal damage. |
| Cholecystectomy / gallbladder removal | Surgical removal of the gallbladder. |
| Gastroparesis | Severe or permanent stomach paralysis. |
| Cyclical or persistent vomiting | Lasting at least 4 weeks; must require hospitalization, ER visit, or medical treatment. |
| GI injury requiring surgery | Including GI injuries requiring hospitalization with no clear current diagnosis. |
| DVT or pulmonary embolism | Deep vein thrombosis or PE and related injuries, including death. |
| Suicide | Medical treatment is not required for this category. |
| Acute necrotizing encephalopathy (ANE) | Brain inflammation with tissue death. |
| Malnutrition-related disorders | Including sarcopenia (muscle wasting). |
| Wernicke encephalopathy | Brain disorder caused by thiamine deficiency. |
| Clinically significant vitamin deficiencies | Requiring medical treatment. |
| Kidney injury or renal failure | Caused by GI complications such as dehydration from vomiting. |
| NAION | Non-arteritic anterior ischemic optic neuropathy — sudden vision loss. Learn more about NAION claims. |
NOT ELIGIBLE: Cases in which the only diagnosis is pancreatitis, or the only diagnosis is pancreatic cancer, are not currently being accepted under the present case-acceptance criteria for these claims. If you have a pancreatitis or pancreatic-cancer diagnosis along with one of the qualifying injuries above, we are still interested in talking to you.
Eligibility Windows by Medication and Injury
FDA labels for these medications were updated on different dates to disclose specific risks. If you began taking a particular medication after the date its label was updated for the injury you suffered, the manufacturer has a strong defense that it warned of the risk, and we will not be able to take the case.
| Injury claimed | Medication | Disqualified if usage began after |
|---|---|---|
| Ileus & intestinal blockages only | Rybelsus | September 23, 2022 |
| Ileus & intestinal blockages only | Wegovy | February 6, 2023 |
| Ileus & intestinal blockages only | Ozempic | September 22, 2023 |
| Ileus & intestinal blockages only | Mounjaro | September 22, 2023 |
| Pulmonary aspiration only | Mounjaro | January 2024 |
| Pulmonary aspiration only | Ozempic | November 2024 |
| Severe GI reactions only | Ozempic | January 2025 |
| Kidney injury due to dehydration only | Mounjaro | May 2025 |
Common Disqualifiers
Even if you took a brand-name medication for at least 30 days and were diagnosed with a qualifying injury, the following circumstances will disqualify a claim. We screen every intake for these:
- No medical treatment was sought or documented for the alleged injury.
- Prior abdominal surgery on or near the stomach that could have injured the vagus nerve.
- For DVT claims: the injured person was 50 or older, and the DVT occurred during a hospitalization (a recognized non-medication risk factor).
- For Ozempic-only cholecystectomy/gallbladder removal claims: GLP-1 use began after March 2022.
- Claim involves only pancreatitis or only pancreatic cancer (no other qualifying injury).
- The medication was compounded (see eligibility above).
Why a Pennsylvania Firm for the Ozempic MDL?
The federal Glucagon-Like Peptide-1 Receptor Agonists MDL is consolidated in the United States District Court for the Eastern District of Pennsylvania. Our firm regularly practices in EDPA, and Mr. Siddons is admitted to the bar of the Eastern District. Working with a Pennsylvania firm for an MDL venued in Pennsylvania means working with attorneys who know the local rules, the bench, and the scheduling orders that govern these proceedings — practical advantages once a case is on the docket.
What to Expect If You Engage Our Firm
Mass-tort pharmaceutical litigation is specialized, document-intensive work. We evaluate, build, and pursue GLP-1 matters on a contingency-fee basis: there is no out-of-pocket cost to you, and there is no fee unless we recover compensation. The contingency rate and litigation-cost terms are set out in the engagement paperwork you review and sign before any work begins.
GLP-1 Medication Injury FAQ
What side effects of Ozempic and other GLP-1 medications are grounds for a lawsuit?
The qualifying injuries under the current case-acceptance criteria are listed in the table above. They include gastroparesis, ileus or bowel obstruction, intraoperative pulmonary aspiration, esophageal injury requiring surgery, cholecystectomy/gallbladder removal, cyclical or persistent vomiting, GI injury requiring surgery, DVT or pulmonary embolism, suicide, acute necrotizing encephalopathy, malnutrition-related disorders including sarcopenia, Wernicke encephalopathy, vitamin deficiencies requiring treatment, kidney injury or renal failure caused by dehydration from GI symptoms, and NAION (sudden vision loss). Pancreatitis or pancreatic cancer alone are not currently being accepted.
How long do I have to file a GLP-1 medication injury lawsuit?
Statutes of limitations vary by state and by injury type, and the clock can begin to run on the date of injury, the date of diagnosis, or the date you reasonably should have known the injury was caused by the medication. In Pennsylvania, the personal-injury statute of limitations is generally two years; New Jersey is two years; Maryland is three years; New York is three years (with a separate discovery rule for certain product injuries). The safest answer is to call us promptly — the engagement does not commit you to filing, but it stops the limitations clock for purposes of our investigation.
What compensation can I receive from an Ozempic or GLP-1 medication lawsuit?
Compensation in mass-tort drug cases typically includes medical expenses (past and future), lost wages and lost earning capacity, pain and suffering, and in some cases punitive damages where the manufacturer’s conduct supports them. Specific values depend on injury severity, medical documentation, and the settlement matrix that develops in the MDL. We do not promise specific dollar outcomes; we promise an honest evaluation.
Do I need to have had surgery to qualify for a claim?
Not always. Surgery is required for some injury categories (esophageal injury requiring surgery, GI injury requiring surgery, cholecystectomy). For others — gastroparesis, cyclical vomiting, kidney injury — documented hospitalization, ER visits, or sustained medical treatment can satisfy the requirement. The one injury for which no medical treatment is required is suicide.
What if I took a compounded version of semaglutide instead of brand-name Ozempic or Wegovy?
Compounded semaglutide does not qualify under the current case-acceptance criteria. Only the eight brand-name medications listed at the top of this page qualify. If you took a compounded product — common during the 2023–2024 GLP-1 shortage — read our dedicated compounded-semaglutide page for honest information about your situation.
I’ve heard that some people are blaming GLP-1 medications for mental health problems. Is that a valid legal claim?
Suicide is one of the qualifying injury categories. Other mental-health symptoms (depression, anxiety, mood changes) are part of the broader literature on GLP-1 adverse events, but standing alone they do not currently meet the case-acceptance criteria. If a mental-health symptom led to a suicide attempt or completed suicide, please call us.
What’s the difference between my doctor prescribing a medication and the manufacturer being liable for my injury?
Mass-tort drug litigation focuses on the manufacturer’s duty to warn about known risks. A prescribing physician relies on the FDA-approved label and the manufacturer’s post-market communications. If the manufacturer failed to disclose a risk in time for the prescriber to weigh it, the manufacturer can be liable to the patient even though the doctor wrote the prescription. The date-cutoff table on this page reflects when the FDA labels were updated for each specific risk.
Talk to Us
There is no cost to have your potential GLP-1 case evaluated. Call our office or complete the screening questionnaire at the top of this page — it walks through every eligibility criterion above so you can see for yourself whether your claim is likely to qualify.
We serve injured patients across Pennsylvania, New Jersey, New York, and Maryland. Whether you live in Philadelphia, Newark, New York City, Baltimore, or anywhere in between, we’re ready to evaluate your claim.
Schedule Your Free Consultation Today